Project Grant HT94252310749
Award Date 8/15/23
Completion Date 8/14/26
Dollars Obligated $817K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Sarasota, FL 34243, USA
Similar Awards
- The Defense Health Agency awarded The Roskamp Institute, Inc. a $817,085 Project Grant under the Military Medical Research and Development program to conduct research on amnion cell secretome-mediated therapy for traumatic brain injury. The three-year award runs from June 1, 2023 to May 31, 2026 and will support The Roskamp Institute's investigation into potential therapies using amnion-derived cell treatments to address neuroinflammation and other vascular contributions to traumatic brain...
- The U.S. Defense Health Agency awarded a $817,200 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will support a 3-year research project titled "Targeting APOE Bioenergetics for Reducing the Risk of Neurodegeneration After Chronic Traumatic Brain Injury." The research aims to investigate mitochondrial bioenergetics, tau protein pathology,...
- The Defense Health Agency awarded a $1,633,104 Project Grant to The Roskamp Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420) to develop highly selective DYRK1A inhibitors as a novel therapeutic approach for traumatic brain injury. The grant, which runs from June 15, 2024 to June 14, 2028, supports the organization's research to understand the causes of and find cures for neuropsychiatric and neurodegenerative disorders. The Roskamp Institute, a non-profit...
- The Defense Health Agency awarded a $489,997 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will fund research to delineate the therapeutic effect of PTEN inhibition on mitigating chronic microglia activation and the chronic sequelae of repetitive mild traumatic brain injury (mTBI). The Roskamp Institute, a non-profit biotechnology research organization, has...
- This federal Project Grant award for $327,194 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc., a biotechnology research organization based in Sarasota, Florida. The purpose of this 3-year award, with a performance period from September 1, 2024 to August 31, 2027, is to conduct research on delineating the therapeutic effect of PTEN inhibition for mitigating chronic microglia activation and the...
- Federal Project Grant Award Summary The Roskamp Institute, Inc. received a $3.27 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded on September 15, 2025, with performance extending through September 14, 2029. The award funds research to delineate the therapeutic effects of a novel blood-brain barrier (BBB)-penetrable peroxisome proliferator-activated receptor (PPAR) agonist on chronic outcomes following...
- The Defense Health Agency awarded a $749,905 Project Grant to The Roskamp Institute Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2023 through September 2026 to investigate microglial NOX2/NLRP3 inflammasome activation and its role in driving tau pathology and cognitive impairments in chronic traumatic brain injury. Specifically, the Roskamp Institute will conduct basic, applied, and advanced biomedical...
- This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $713,277 to Boston University Medical Campus to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness. The award will support the project from September 1, 2024 through August 31, 2027. As part of this...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded Scripps Research Institute, a nonprofit biomedical research organization, a $529,125 project grant to investigate microglia dysfunction in MEF2C deficiency autism spectrum disorder with the goal of discovering targeted therapies. This 3-year award, effective September 30, 2024, will fund research aimed at improving the health and care of military service members, veterans, and their families...
- The Defense Health Agency has awarded a $760,844.00 Project Grant to the Texas A&M University System Health Science Center to conduct research under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, awarded on September 15, 2023 with a completion date of September 14, 2026, will fund research titled "Targeting the MIF/CD74 Immune Axis to Treat GWI Astrocyte, Neuronal, and Cognitive Dysfunction." This research aims to investigate medical...